Schwartz D D, Clark T P
Department of Anatomy, Physiology and Pharmacology, Auburn University, College of Veterinary Medicine, Alabama 36849, USA.
J Vet Pharmacol Ther. 1998 Oct;21(5):342-7. doi: 10.1046/j.1365-2885.1998.00151.x.
The alpha2-adrenergic receptor antagonists, yohimbine, atipamezole and tolazoline, are used in veterinary medicine as reversal agents for the sedative/hypnotic effects of alpha2-agonists. Ruminants have increased sensitivity to the sedative/hypnotic effects of alpha2-agonists compared to other species. The receptors mediating the sedative effects of alpha2-agonists are located primarily on locus coeruleus neurons in the pons of the lower brainstem. Four pharmacological subtypes of the alpha2-adrenergic receptor (A,B, C and D) have been identified based on differences in ligand affinity. The aim of this study was to: 1) determine the pharmacological profile of atipamezole, yohimbine and tolazoline at the four alpha2-adrenergic receptor subtypes and; 2) determine whether these agents differ in their affinities at the alpha2-adrenergic receptor present in the sheep brainstem. In inhibition binding studies against the selective alpha2-adrenergic receptor ligand [3H]-MK-912, tolazoline showed the lowest affinity for all four alpha2-adrenergic receptor subtypes compared to yohimbine and atipamezole. The affinities of yohimbine and atipamezole were similar at the alpha2A-, alpha2B- and alpha2C-adrenergic receptors but differed by approximately 100 fold at the alpha2D-adrenergic receptor. Atipamezole had a 100 fold higher affinity at the alpha2D-adrenergic receptor when compared to yohimbine. To determine the ligand binding characteristics of these agents at the alpha2-adrenergic receptor in sheep brainstem, membranes were labelled with [3H]-MK-912 and inhibition competition curves were performed. Atipamezole showed approximately a 100 fold higher affinity for the sheep brainstem alpha2-adrenergic receptor compared to yohimbine which was similar to what was observed for the alpha2D-adrenergic receptor in PC12 cells transfected with RG-20. The results from these studies suggest that atipamezole has a high affinity for the alpha2D-adrenergic receptor that appears to be the receptor subtype in sheep brainstem.
α2 - 肾上腺素能受体拮抗剂育亨宾、阿替美唑和妥拉唑啉在兽医学中用作α2 - 激动剂镇静/催眠作用的苏醒剂。与其他物种相比,反刍动物对α2 - 激动剂的镇静/催眠作用更为敏感。介导α2 - 激动剂镇静作用的受体主要位于脑桥下部脑干的蓝斑核神经元上。基于配体亲和力的差异,已鉴定出α2 - 肾上腺素能受体的四种药理学亚型(A、B、C和D)。本研究的目的是:1)确定阿替美唑、育亨宾和妥拉唑啉在四种α2 - 肾上腺素能受体亚型上的药理学特征;2)确定这些药物对绵羊脑干中存在的α2 - 肾上腺素能受体的亲和力是否存在差异。在针对选择性α2 - 肾上腺素能受体配体[3H] - MK - 912的抑制结合研究中,与育亨宾和阿替美唑相比,妥拉唑啉对所有四种α2 - 肾上腺素能受体亚型的亲和力最低。育亨宾和阿替美唑在α2A - 、α2B - 和α2C - 肾上腺素能受体上的亲和力相似,但在α2D - 肾上腺素能受体上相差约100倍。与育亨宾相比,阿替美唑在α2D - 肾上腺素能受体上的亲和力高100倍。为了确定这些药物在绵羊脑干α2 - 肾上腺素能受体上的配体结合特征,用[3H] - MK - 912标记膜并绘制抑制竞争曲线。与育亨宾相比,阿替美唑对绵羊脑干α2 - 肾上腺素能受体的亲和力高约100倍,这与在用RG - 20转染的PC12细胞中观察到的α2D - 肾上腺素能受体的情况相似。这些研究结果表明,阿替美唑对α2D - 肾上腺素能受体具有高亲和力,该受体似乎是绵羊脑干中的受体亚型。